Table 2. Baseline demographic data of the participants and comparison of anthropometric, clinical, and laboratory characteristics and use of combination therapy with DPP-4 inhibitor plus vitamin D between remitters and non-remitters.
| Remitters (n = 27) | Non-remitters (n = 19) | P value | |
|---|---|---|---|
| Age at diagnosis (years) | 13.89 ± 7.0 | 11.05 ± 5.1 | 0.056 |
| Females – n (%) | 12 (44.4%) | 11 (57.8%) | 0.54 |
| Males – n (%) | 15 (55.5%) | 8 (42.1%) | 0.54 |
| BMI (kg/m2) | 19.07 ± 3.68 | 15.86 ± 2.49 | 0.002 |
| BMI z-score | -0.26 ± 1.12 | -1.12 ± 1.69 | 0.11 |
| DKA at diagnosis – n (%) | 10 (38.46%) | 9 (47.37%) | 0.76 |
| FPG (mg/dL) | 262.4 ±101.9 | 294.1 ± 138.4 | 0.43 |
| HbA1c (%) | 10.7 ± 2.60 | 10.5 ± 2.91 | 0.78 |
| TDD (IU/kg of body weight/24h) | 0.46 ± 0.31 | 0.53 ± 0.21 | 0.21 |
| 25(OH)D (ng/mL) | 29.55 ± 14.9 | 36.78 ± 9.29 | 0.066 |
| Fasting C peptide (ng/mL) | 0.81 ± 0.49 | 0.84 ± 0.69 | 0.060 |
| Hashimoto's thyroiditis | 5 (18.5%) | 3(15.78%) | 0.715 |
| VIDPP-4i use | 21 (77.78%) | 6 (31.58%) | 0.0025 |
Data are presented as mean ± standard deviation or frequency (percentage). Abbreviations: 25(OH)D, serum 25-hydroxyvitamin D levels; BMI, body mass index; DKA, diabetic ketoacidosis, FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; n, number of patients with data available for statistical analysis; SD, standard deviation; TDD, total daily insulin dose; VIDPP-4i, combination therapy with DPP-4 inhibitor plus vitamin D.